Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells - PubMed (original) (raw)
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells
Jonathan M Irish et al. Blood. 2006.
Abstract
The B-cell receptor (BCR) transmits life and death signals throughout B-cell development, and altered BCR signaling may be required for survival of B-lymphoma cells. We used single-cell signaling profiles to compare follicular lymphoma (FL) B cells and nonmalignant host B cells within individual patient biopsies and identified BCR-mediated signaling events specific to lymphoma B cells. Expression of CD20, Bcl-2, and BCR light chain isotype (kappa or lambda) distinguished FL tumor B-cell and nontumor host B-cell subsets within FL patient biopsies. BCR-mediated signaling via phosphorylation of Btk, Syk, Erk1/2, and p38 occurred more rapidly in tumor B cells from FL samples than in infiltrating nontumor B cells, achieved greater levels of per-cell signaling, and sustained this level of signaling for hours longer than nontumor B cells. The timing and magnitude of BCR-mediated signaling in nontumor B cells within an FL sample instead resembled that observed in mature B cells from the peripheral blood of healthy subjects. BCR signaling pathways that are potentiated specifically in lymphoma cells should provide new targets for therapeutic attention.
Figures
Figure 1.
Distinguishing BCR signaling events and FL biopsy cell subsets by flow cytometry. (A) Phosphoproteins detected by flow cytometry (dark blue rings) are highlighted on a model of BCR signaling that includes regulation by protein tyrosine phosphatases. The BCR can instruct B cells to proliferate, alter innate immune signaling thresholds, induce B-cell anergy, or initiate cell death in a manner thought to depend on the strength, duration, and path of signaling. We detected BCR-mediated phosphorylation of Syk, Btk, Erk1/2, and p38 in subsets of primary human B cells. (B) Flow cytometry analysis of light chain isotype of CD20+ cells from a peripheral blood mononuclear cell (PBMC) sample (healthy donor), an FL tumor biopsy specimen from a different patient (FL-P12), and the Ramos lymphoma cell line. Ramos cells are clonal in origin and were of λ isotype. FL tumor cells in FL-P12 were κ isotype and vastly outnumbered the TIL B cells, as is commonly observed in FL tumor biopsy specimens. (C) Flow cytometry analysis of an FL biopsy specimen with an unusually large number of infiltrating nonmalignant B cells (FL-P10). Analysis of light chain isotypes present in the CD20+ subset of cells suggested that the tumor B cells were κ isotype and indicated that all B cells in the sample were exclusively κ or λ isotype. Expression of λ isotype was compared with Bcl-2 expression to identify FL tumor and nonmalignant B-cell populations. FL tumor B cells were κ isotype and overexpressed Bcl-2. Nonmalignant tumor-infiltrating host B cells did not overexpress Bcl-2 and were either κ or λ isotype. CD20 expression was also compared with Bcl-2 and with λ light chain expression in the total population of cells in the sample.
Figure 2.
Activation of BCR signaling varies among primary FL samples and contrasts with that of normal B cells and a lymphoma cell line. (A) Flow cytometry analysis of signaling in PBMCs from a healthy blood donor, Ramos cells, and 5 FL patient samples (FL-P07–11) stimulated by BCR cross-linking (α-μ/γ) for various times in a short time course (1, 2, 4, 8, or 16 minutes) or left unstimulated (0 minute). BCR-mediated signaling in the CD20+ B-cell subset was compared by coloring heat map squares relative to the unstimulated PBMC sample. (B) As in panel A, with the addition of H2O2 just prior to BCR cross-linking. (C) Histogram data underlying the heat maps in panels A and B are shown for 2 samples, the lymphoma cell line Ramos and FL-P08.
Figure 3.
Rapid activation of BCR-mediated signaling in the presence of H2O2 is a common feature of FL sample B cells and differs from normal PBMC B cells. Differences in initiation of BCR-mediated signaling were compared in 5 tumor biopsy samples from individuals with FL and 5 PBMC samples from healthy donors. Samples were stimulated for 4 minutes by a combination of BCR cross-linking and H2O2 (α-μ/γ + H2O2) or left unstimulated. The average MFI of each phosphoprotein in CD20+ B cells has been graphed. Error bars indicate standard deviation.
Figure 4.
Altered BCR signaling kinetics distinguish individual FL samples. BCR-mediated phosphorylation of Btk, Syk, Erk1/2, and p38 was observed at numerous times over a 2-hour time course in 3 representative FL samples (FL-P07, FL-P10, FL-P11). Cells were stimulated by BCR cross-linking and H2O2 (α-μ/γ + H2O2) or left unstimulated (0 minute), and the MFI of CD20+ B cells was graphed for each phosphoprotein. The area under the curve has been shaded to indicate the sum of signaling induction over time in B cells from each FL sample. As a reference, the same plot of the average MFI and standard deviation observed in 3 samples of normal PBMCs (PBMC Average) is shown on each graph.
Figure 5.
Tumor cell–specific BCR-mediated Btk, Syk, Erk1/2, and p38 signaling. Flow cytometry contour plots of FL patient biopsy cells (FL-P09) stimulated by BCR cross-linking plus H2O2 (α-μ/γ + H2O2) for 4 or 30 minutes or left unstimulated (0 minute). BCR-mediated phosphorylation of Btk, Syk, Erk1/2, and p38 was compared in FL B cells (CD20+ Bcl-2hi λ–, dark arrow) and nonmalignant B cells (CD20hi Bcl-2lo, light arrow).
Figure 6.
Tumor cell–specific BCR-mediated Syk signaling. (A) Flow cytometry contour plots of FL patient biopsy cells (FL-P10) stimulated by BCR cross-linking alone (α-μ/γ) or by a combination of BCR cross-linking and H2O2 (α-μ/γ+ H2O2) for various times (4, 16, 30, 60, 90 minutes) or left unstimulated (0 minute). BCR-mediated phosphorylation of Syk was compared in CD20+ Bcl-2+ FL B cells and CD20+ Bcl-2– nonmalignant B cells (refer to Figure 1). Dark arrows indicate greater Syk signaling in Bcl-2+ FL tumor B cells than in nonmalignant host B cells. Light arrows indicate λ isotype B cells that failed to activate Syk in response to BCR cross-linking. (B) Flow cytometry contour plots of FL patient biopsy cells (FL-P10) stimulated by a combination of BCR cross-linking and H2O2 (α-μ/γ + H2O2) for various times (4, 16, 30, 60, or 90 minutes) or left unstimulated (0 minute). BCR-mediated phosphorylation of Syk was measured in CD20+ κ isotype B cells and compared with that in λ isotype nonmalignant B cells (all λ– cells are κ+). Dark arrows indicate sustained Syk signaling in Bcl-2+ FL tumor B cells. Light arrows indicate where Syk signaling in λ isotype B cells differed from κ isotype B cells.
Figure 7.
Tumor cell–specific BCR-mediated signaling is common in FL. (A) BCR-mediated signaling at 4 and 30 minutes following BCR cross-linking in the presence of H2O2 (α-μ/γ+ H2O2) was measured in subsets of the CD20+ B cells from 4 FL patient samples (FL-P07, FL-P08, FL-P09, FL-P11). FL B cells (CD20+ Bcl-2hi nontumor light chain–, dark arrow) and tumor-infiltrating nonmalignant B cells (CD20+ Bcl-2lo nontumor light chain+, light arrow) were distinguished and their signaling was compared by coloring heat map squares relative to the fold induction of phosphorylation relative to the unstimulated sample (0 minute). (B) Flow cytometry analysis of FL patient biopsy cells (FL-P12) stimulated by a combination of BCR cross-linking and H2O2 (α-μ/γ+ H2O2) for various times (4, 30, 60, or 90 minutes) or left unstimulated (0 minute). BCR-mediated phosphorylation of Erk1/2 and p38 was measured in nonmalignant B cells (CD20+ λ isotype, light arrow) and compared with that in FL B cells (CD20+ Bcl-2+ λ–, dark arrow).
Similar articles
- B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.
Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R. Irish JM, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12747-54. doi: 10.1073/pnas.1002057107. Epub 2010 Jun 11. Proc Natl Acad Sci U S A. 2010. PMID: 20543139 Free PMC article. - Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.
Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K. Wogsland CE, et al. Cytometry B Clin Cytom. 2017 Jan;92(1):79-87. doi: 10.1002/cyto.b.21498. Cytometry B Clin Cytom. 2017. PMID: 27933753 Free PMC article. - DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.
Amin R, Mourcin F, Uhel F, Pangault C, Ruminy P, Dupré L, Guirriec M, Marchand T, Fest T, Lamy T, Tarte K. Amin R, et al. Blood. 2015 Oct 15;126(16):1911-20. doi: 10.1182/blood-2015-04-640912. Epub 2015 Aug 13. Blood. 2015. PMID: 26272216 Free PMC article. - Follicular lymphoma (FL): Immunological tolerance theory in FL.
García-Muñoz R, Panizo C. García-Muñoz R, et al. Hum Immunol. 2017 Feb;78(2):138-145. doi: 10.1016/j.humimm.2016.09.010. Epub 2016 Sep 30. Hum Immunol. 2017. PMID: 27693433 Review. - B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V, Mraz M. Seda V, et al. Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25080849 Review.
Cited by
- B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, Giacobazzi L, Caligola S, Adamo A, Putta S, Aparo A, Ferrarini I, Ugel S, Giugno R, Donadelli M, Dando I, Krampera M, Visco C, Scupoli MT. Gambino S, et al. Sci Rep. 2024 Mar 19;14(1):6595. doi: 10.1038/s41598-024-55728-9. Sci Rep. 2024. PMID: 38503806 Free PMC article. - Targeted Treatment of Follicular Lymphoma.
Nath K, Gandhi MK. Nath K, et al. J Pers Med. 2021 Feb 22;11(2):152. doi: 10.3390/jpm11020152. J Pers Med. 2021. PMID: 33671658 Free PMC article. Review. - Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Sender S, Sekora A, Villa Perez S, Chabanovska O, Becker A, Ngezahayo A, Junghanss C, Murua Escobar H. Sender S, et al. Int J Mol Sci. 2021 Jan 8;22(2):592. doi: 10.3390/ijms22020592. Int J Mol Sci. 2021. PMID: 33435587 Free PMC article. - The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. Fowler NH, et al. Br J Haematol. 2020 May;189(4):650-660. doi: 10.1111/bjh.16424. Epub 2020 Mar 16. Br J Haematol. 2020. PMID: 32180219 Free PMC article. - Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response.
Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM. Huse K, et al. Cytometry A. 2019 Apr;95(4):442-449. doi: 10.1002/cyto.a.23737. Epub 2019 Mar 5. Cytometry A. 2019. PMID: 30838773 Free PMC article.
References
- Fleming HE, Paige CJ. Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. Immunity. 2001;15: 521-531. - PubMed
- Reth M, Wienands J. Initiation and processing of signals from the B cell antigen receptor. Annu Rev Immunol. 1997;15: 453-479. - PubMed
- Allman D, Srivastava B, Lindsley RC. Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells. Immunol Rev. 2004;197: 147-160. - PubMed
- Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 1993;72: 325-335. - PubMed
- Casellas R, Shih TA, Kleinewietfeld M, et al. Contribution of receptor editing to the antibody repertoire. Science. 2001;291: 1541-1544. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous